Specifically, it is tempting to postulate that BAL0891s unique profile could potentially alleviate the primary dose-limiting toxicity associated with PLK1-and TTK-specific inhibitors; namely hematologic toxicity (including neutropenia) (19, 48). This evidence concerns the gene TTK and neutropenia.